Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC
Watch Lonza's latest callLonza Group (SIX Swiss: LONN) Q2 2026 Earnings Call · Replay · Jul 22Read the transcript of Lonza Group (SIX Swiss: LONN) Q2 2026 Earnings CallThe original release is unavailable here.
Earlier from Lonza
- Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez as Chief Quality Officer
- Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook
- Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Structure
- Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
- Lonza Announces Results of the 2025 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Later from Lonza
- Lonza Nominates Claudia Süssmuth-Dyckerhoff as Board Member
- Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDMO and CHI Businesses
- GBI Biomanufacturing Announces the Appointment of Jesse McCool, Ph.D. as President
- Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs
- Lonza Delivers Strong Profitable Growth in Full-Year 2025 and Successfully Completes Vacaville Site Integration
Follow Lonza into a list and get an email when it puts out news.
Follow Lonza